Show results for
Refine by
Solid Tumor Suppliers Serving Idaho
95 companies found
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
Strong scientific and clinical rationale for LSD1/HDAC6 inhibition in haematological and solid ...
based inTel-Aviv, ISRAEL
RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on our promises, to build a company at the forefront of ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
CYNK-001 is the only cryopreserved, allogeneic, off-the-shelf, natural killer (NK) cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid ...
based inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive ...
based inSaint Louis, MISSOURI (USA)
Sequoia Vaccines is a clinical stage pharmaceutical company discovering and developing new vaccines preventing bacterial infections and medicines treating cancers and bacterial infections. Sequoia’s lead clinical candidate is a vaccine for the ...
Sequoia is developing an anticancer compound (SQ1274) for use against solid tumors including ovarian and lung ...
based inYuseong-gu, SOUTH KOREA
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since ...
PMC-403 is a monoclonal antibody that targets the human TIE2 that regulate the angiogenesis and vessel maturation in endothelial cells. It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky blood vessels in eyes ...
based inBerkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
Natural killer (NK) cells, as their name implies, play an important role in ridding the body of cancer and viruses. NK cells are emerging as an increasingly important cell type for therapeutic development. Solid ...
based inXiamen, CHINA
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer ...
based inFlorence, ITALY
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, ...
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-342 is a bispecific antibody comprised of an anti-GPC3 antagonistic antibody linked to a 4-1BB (CD137) agonistic anticalin ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled ...
based inBellevue, WASHINGTON (USA)
EMulate Therapeutics is a clinical-stage therapeutic device company utilizing its patented proprietary radio frequency energy (RFE) technology, targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®), to provide safe and effective ...
Cellsana is pivotal (phase III) trial ready for treatment of Glioblastoma (GBM) and Diffuse Midline Glioma ...
based inNew Haven, CONNECTICUT (USA)
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge ...
BXCL701 (talabostat) is an investigational, oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 and DPP 4—which triggers inflammasome to alert and prime immune cells, leading to induction of IL-18 and ...
based inWaltham, MASSACHUSETTS (USA)
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are ...
based inPalo Alto, CALIFORNIA (USA)
Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and ...
based inSherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
The HERV-E target is one of the quiescent Human Endogenous Retro-Virus (HERV) sequences that are turned on during tumor development. Its expression in renal cell carcinoma (RCC) is highly selective, with no transcripts detected in ...
based inBerkeley, CALIFORNIA (USA)
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies. Actym is also developing a broad pipeline of additional therapeutic candidates intended to treat checkpoint refractory ...
The company has developed an attenuated, microbial-based, technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid ...